Kabeer Aziz - Dec 19, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Award	$0	+8.97K	$0.00	8.97K	Dec 19, 2024	Direct	F1
holding	ANTX	Common Stock					2M	Dec 19, 2024	See Footnote	F2
holding	ANTX	Common Stock					378K	Dec 19, 2024	See Footnote	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
F2	Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F3	Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.